Federal Register #2026-18877

Exclusive Patent License for Engineered Cell Therapies Targeting HPV 16 E6-Expressing Cancers

The National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, is considering granting an exclusive patent license for engineered T cell therapies targeting HPV 16 E6-expressing cancers. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (HHS) - OEM/Vendor: - MedGene Therapeutics, Inc. - Products/Services Requested: - Exclusive patent license for a family of patents and patent applications covering T cell receptor (TCR) therapies reactive to HPV16 E6 oncoprotein - Intended for the treatment of HPV-associated cervical, head and neck (including oropharyngeal), and anogenital cancers - Field of use: ex vivo generated T cell therapy products comprising autologous or allogeneic T cells genetically engineered to express exogenous TCRs reactive to HPV16 E6 - Unique/Notable Requirements: - License territory may include Japan, Republic of Korea, and the United States - License will be royalty bearing - This is a technology transfer opportunity for intellectual property rights, not a procurement of physical products or services - NCI is accepting written comments and license applications for consideration

Description

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an Exclusive Patent License to MedGene Therapeutics, Inc. for inventions related to engineered T cell therapies targeting HPV 16 E6-expressing cancers. The license covers patents and patent applications for T cell receptor therapies reactive to HPV16 E6 oncoprotein, aimed at treating HPV-associated cervical, head and neck, and anogenital cancers. The license territory may include Japan, Republic of Korea, and the United States, and the license will be royalty bearing. Written comments or license applications must be received by September 30, 2026 to be considered.

View original listing